In conclusion, our data demonstrated that the FGF2-FGFR1 pathway is upregulated in the pemetrexed-resistant NSCLC cells lines and that knockdown of FGF2 by siRNA or the addition of an anti-FGFR1 antibody could partially restore the sensitivity to pemetrexed without altering TS expression. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.